Skip to content
Bored Studies
RecruitingPhase 3

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

Merck Sharp & Dohme LLC · NCT07705555

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
960
US sites recruiting
28
Study start
August 27, 2026
Record last updated
October 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person.

The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.

Being studied: MK-8748; Aflibercept

Conditions: Diabetic Retinopathy; Macular Edema

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

  • Has Type 1 or Type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%
  • Has a decrease in vision in the study eye determined by the Investigator to be primarily the result of diabetic macular edema (DME)
  • For participants who are treatment-naïve for DME, the diagnosis must have been made within 9 months of screening. For all treatment-experienced participants, the first treatment should have been no longer than 3 years prior to the Screening visit

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

  • Has had renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis or has renal failure anticipated to require hemodialysis or peritoneal dialysis at any time during the study
  • Has history of stroke (cerebral vascular accident) or myocardial infarction within 180 days to first dose of study intervention
  • Has newly diagnosed or previously untreated diabetes mellitus and initiated oral or injectable anti-diabetic medication within 3 months to first dose of study intervention
  • Has history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening
  • Has any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy in the study eye within 90 days of screening
  • Has advanced or uncontrolled glaucoma in the study eye
  • Has any history of retinal detachment or treatment or surgery for retinal detachment in the study eye
  • Has active retinal disease other than the condition under investigation in the study eye
  • Has uncontrolled blood pressure at screening

Recruiting US locations

  • Associated Retina Consultants, Ltd ( Site 0084)

    Gilbert, AZ 85297

    Site contact: Study Coordinator · 480-999-5458

  • Global Research Management ( Site 0066)

    Glendale, CA 91204

    Site contact: Study Coordinator · 818-246-2560

  • Retinal Consultants Medical Group ( Site 0013)

    Sacramento, CA 95825

    Site contact: Study Coordinator · 916-974-9279

  • Retina Specialists of Colorado ( Site 0068)

    Denver, CO 80222

    Site contact: Study Coordinator · 720-443-2425

  • Retina Consultants ( Site 0065)

    Manchester, CT 06042

    Site contact: Study Coordinator · 860-646-7704

  • Vitreo Retinal Associates ( Site 0042)

    Gainesville, FL 32607

    Site contact: Study Coordinator · 352-519-5621

  • Retina Care Specialists ( Site 0095)

    Palm Beach Gardens, FL 33410

    Site contact: Study Coordinator · 561-624-0099

  • Retina Vitreous Associates of Florida ( Site 0034)

    Tampa, FL 33617

    Site contact: Study Coordinator · 813-987-2000

  • Florida Retina Institute ( Site 0105)

    Wildwood, FL 34785

    Site contact: Study Coordinator · 877-357-3846

  • Midwest Eye Institute ( Site 0113)

    Carmel, IN 46032

    Site contact: Study Coordinator · 317-805-2152

  • Retina Associates LLC ( Site 0024)

    Lenexa, KS 66215

    Site contact: Study Coordinator · 913-831-7400

  • Mid Atlantic Retina ( Site 0062)

    Hagerstown, MD 21740

    Site contact: Study Coordinator · 301-671-2400

  • Retina Specialists ( Site 0074)

    Towson, MD 21204

    Site contact: Study Coordinator · 410-296-9748

  • Mississippi Retina Associates, P.A. ( Site 0061)

    Madison, MS 39110

    Site contact: Study Coordinator · 601-981-4091

  • Envision Ocular, LLC ( Site 0039)

    Bloomfield, NJ 07003

    Site contact: Study Coordinator · 973-707-5632

  • Retina Associates of Western NY, PC ( Site 0038)

    Rochester, NY 14620

    Site contact: Study Coordinator · 585-442-3411

  • North Carolina Retina Associates ( Site 0064)

    Wake Forest, NC 27587

    Site contact: Study Coordinator · 919-782-8038

  • Charleston Neuroscience Institute ( Site 0087)

    Bluffton, SC 29910

    Site contact: Study Coordinator · 843-763-4466

  • Palmetto Retina Center ( Site 0063)

    Florence, SC 29501

    Site contact: Study Coordinator · 803-931-0077

  • Charleston Neuroscience Institute ( Site 0022)

    Mt. Pleasant, SC 29464

    Site contact: Study Coordinator · 843-763-4466

  • Palmetto Retina Center ( Site 0014)

    West Columbia, SC 29169

    Site contact: Study Coordinator · 8039310077x124

  • Southeastern Retina Associates PC ( Site 0071)

    Johnson City, TN 37604

    Site contact: Study Coordinator · 423-578-4364

  • Southeastern Retina Associates PC ( Site 0018)

    Knoxville, TN 37922-3572

    Site contact: Study Coordinator · 865-934-3866

  • Austin Retina Associates ( Site 0008)

    Austin, TX 78705

    Site contact: Study Coordinator · 512-451-0103

  • Retina Consultants of Texas ( Site 0001)

    Bellaire, TX 77401

    Site contact: Study Coordinator · 713-524-3434

  • Austin Retina Associates ( Site 0080)

    San Marcos, TX 78666

    Site contact: Study Coordinator · 512-451-0103

  • Retina Consultants of Texas ( Site 0029)

    Schertz, TX 78154

    Site contact: Study Coordinator · 210-693-1063

  • Retina Consultants ( Site 0104)

    Charleston, WV 25301

    Site contact: Study Coordinator · 304-346-4400

Study contacts (from the official record)

  • Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
All diabetes studies in Arizona →
A Clinical Trial of MK-8748 Compared to Aflibercept in… (NCT07705555) | Bored Studies